Advertisement
Advertisement
U.S. markets close in 3 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
106.78+0.14 (+0.13%)
As of 12:29PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close106.64
Open109.27
Bid106.40 x 1100
Ask106.46 x 1300
Day's Range106.06 - 109.43
52 Week Range66.59 - 115.95
Volume462,614
Avg. Volume876,738
Market Cap247.712B
Beta (5Y Monthly)0.26
PE Ratio (TTM)35.11
EPS (TTM)3.04
Earnings DateN/A
Forward Dividend & Yield1.47 (1.38%)
Ex-Dividend DateAug 16, 2021
1y Target Est118.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novo Nordisk A/S
    Analyst Report: Novo Nordisk A/SWith almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Insider Monkey

    Here’s Why LRT Capital Finds Novo Nordisk (NVO) as Highly Attractive”

    LRT Capital Management, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. A return of +18.39% was recorded by the LRT Economic Moat strategy year-to-date, extending its 12-month returns to +35.34%. You can take a look at the fund’s top 5 holdings to have an idea […]

  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 29 November 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. Under the programm

  • GlobeNewswire

    Novo Nordisk announces impact from Volume Based Procurement for insulin in China

    Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of a

Advertisement
Advertisement